As some such genes were also sensitive to inhibition of the mevalonate pathway [BRCA1 (63), PCNA (64), MCM2 (65), CDK2 (66) and MCM7 (67)], hub genes may also be involved in the antitumor effects of pathway inhibitors in lung cancer. This evidence concerns the gene CDK2 and lung cancer.